Recent Setbacks and Shareholder Fallout

Corcept Therapeutics (NASDAQ: CORT) – a biotech focused on cortisol-modulating drugs – has been rocked by a series of setbacks. On December 31, 2025, the FDA issued a Complete Response Letter (CRL) rejecting Corcept’s New Drug Application for relacorilant (its lead pipeline drug for Cushing’s syndrome) due to insufficient evidence of effectiveness (www.biospace.com) (www.biospace.com). This surprise FDA rejection wiped out nearly half of Corcept’s market value, as shares plunged ~50% to $34.80 by that day’s close (www.biospace.com). Analysts swiftly slashed expectations – Truist Securities cut its price target from $135 down to $50 after the CRL (www.biospace.com) – reflecting a drastic reassessment of Corcept’s growth prospects. Only weeks later, on February 19, 2026, Corcept lost a key patent appeal: a U.S. federal court ruled that Teva’s generic version of Korlym (Corcept’s sole marketed drug) does not infringe Corcept’s patents (news.bloomberglaw.com). Corcept’s stock sank as much as 25–28% intraday on the patent defeat, hitting its lowest levels since 2024 (news.bloomberglaw.com). The one-two punch of a failed FDA approval and a court loss has erased over $3.6 billion in shareholder value (marketchameleon.com). In the aftermath, multiple law firms have launched shareholder class-action lawsuits alleging Corcept misled investors about relacorilant’s clinical trial results and approval odds (www.globenewswire.com). The class period spans October 31, 2024 through December 30, 2025 – suggesting that investors claim Corcept painted an overly optimistic picture of relacorilant despite red flags in its Phase 3 trials (www.globenewswire.com). (Notably, this isn’t Corcept’s first legal tangle with investors; the company previously settled a 2019 securities class action for $14 million – fully covered by insurers (www.sec.gov).) In short, Corcept enters 2026 under a cloud of litigation and uncertainty, its once-high-flying stock now nearly half off its peak and facing fundamental challenges.

Dividend Policy and Shareholder Returns

Corcept has never paid a dividend on its common stock (www.sec.gov), and management has indicated no plans to initiate any dividends in the foreseeable future (www.sec.gov) (www.sec.gov). As a biotech growth company, Corcept has instead opted to return capital to shareholders via stock buybacks. The Board has authorized substantial share repurchase programs – including a $200 million authorization announced in January 2024 (www.sec.gov). These buybacks have significantly reduced the share count and boosted EPS in recent years. For example, Corcept’s diluted shares outstanding shrank from roughly 126 million in 2021 to about 112 million by 2023, thanks to aggressive repurchases (theedgeinvestor.com). In 2025 alone, the company spent over $170 million buying back ~2.6 million shares in the open market (www.sec.gov) (www.sec.gov). With no dividend yield (0%), stock price appreciation and buybacks have been the only sources of shareholder return (theedgeinvestor.com). These capital return moves reflected management’s confidence in Corcept’s prospects – confidence now being second-guessed given the recent pipeline failure. (Indeed, some critics argue that cash used for repurchases might have been better retained to weather the current storm (theedgeinvestor.com).) AFFO/FFO metrics are not applicable here, as those are REIT cash flow measures; Corcept’s focus is reinvesting in R&D rather than paying out cash flows.

Balance Sheet Strength – Leverage and Maturities

A silver lining for Corcept is its strong balance sheet and negligible leverage. The company carries virtually no interest-bearing debt – no bank loans or bond obligations at all. Total liabilities consist mainly of accounts payable, accrued expenses, lease obligations, and taxes. As of year-end 2025, Corcept’s total liabilities were about $189 million (www.sec.gov), which are modest relative to its asset base and equity. In fact, the company’s current assets (cash, investments, receivables) far exceed all liabilities. Corcept ended 2025 with roughly $532 million in cash and marketable securities on hand (www.sec.gov), only slightly lower than the $603 million one year prior (despite heavy buybacks). This ample liquidity provides a significant cushion for the challenges ahead. Corcept’s debt-to-equity ratio is effectively zero – it was a mere ~0.01 at the end of 2023 (theedgeinvestor.com) and remains extremely low – indicating a virtually unlevered capital structure. With no debt maturities to worry about, the company’s solvency is not in question. Corcept even generates interest income (nearly $22 million in 2025) from its cash investments, given the rising rate environment (www.sec.gov). In short, leverage is not a concern – Corcept’s balance sheet is a source of stability, affording it the capacity to fund R&D or weather temporary cash flow hits without creditor pressure. This conservative financial position is a strategic asset as the company navigates its current setbacks.

Operating Performance and Valuation

Despite being a biotech, Corcept is unusual in that it has an established revenue base and consistent profitability from its flagship product, Korlym. In 2025, Corcept’s product revenue grew to $761 million (up 13% from $675 million in 2024) (www.sec.gov), driven by increased Korlym sales. However, operating expenses surged – notably SG&A jumped to $449 million in 2025 (from $280 million in 2024) as the company expanded its sales force and marketing, perhaps in anticipation of relacorilant’s launch (www.sec.gov). This expense growth squeezed operating income to $45 million (vs. $137 million prior year) (www.sec.gov). Net income for 2025 was $99.7 million (www.sec.gov), aided by a one-time tax benefit; EPS came in at $0.82 (diluted), down from $1.23 in 2024 (www.sec.gov).

Even after the recent stock plunge, Corcept’s valuation multiples remain elevated. At around $35 per share in early 2026, CORT traded near 38× trailing earnings, higher than the ~33× average P/E for small-cap biotech peers (theedgeinvestor.com). In other words, the stock isn’t exactly cheap relative to current earnings, despite the ~50% collapse in price. The market is still embedding significant future growth (or recovery) in Corcept’s valuation. On a price-to-sales basis, CORT is roughly ~4.0× TTM revenue at $30/share. Its enterprise value is somewhat lower given over $500 million in net cash, but EV/sales is still in the ~3.5–4× range – not trivial for a one-product pharma company facing new headwinds. Price/FFO or P/AFFO measures are not relevant here (those apply to real estate firms’ cash flows), so P/E and EV/EBITDA are more appropriate gauges. Bulls might argue Corcept’s forward P/E will compress if earnings grow (e.g. as new indications come to market), but bears counter that at ~38× earnings the stock “leaves little margin for error” (theedgeinvestor.com). The dramatic range of valuation outcomes reflects the binary nature of Corcept’s situation (theedgeinvestor.com) – the stock’s fair value could swing wildly based on whether its pipeline succeeds or its core profits erode under competition.

Key Risks and Red Flags

Corcept’s risk profile has intensified following these events. First and foremost is product concentration risk: the company’s entire revenue comes from a single drug, Korlym (mifepristone for Cushing’s syndrome). Generic competition for Korlym now looms large. The recent appeals court ruling clearing Teva’s generic threatens to erode Corcept’s sales far earlier than investors had hoped (news.bloomberglaw.com). While Corcept had formerly settled with one generic challenger (Hikma) to delay entry until 2034, Teva did not settle (ir.corcept.com) (ir.corcept.com). With the legal win, Teva could seek FDA approval and launch a generic Korlym once the regulatory process allows. A generic entry would likely slash Korlym’s revenue – either through volume loss or forced price cuts – materially harming Corcept’s earnings (www.sec.gov) (www.sec.gov). Notably, Korlym is distributed through specialty channels due to its safety profile (mifepristone’s use requires controlled distribution). Jefferies analysts have pointed out that Teva lacks a specialty pharmacy network for this niche market, so a generic may not immediately capture Korlym’s share until distribution logistics are sorted (news.bloomberglaw.com). Nonetheless, the threat is simply delayed, not eliminated. Even a slower erosion still means Corcept’s core franchise has a limited runway. Furthermore, competing Cushing’s therapies are already on the market – for example, Xeris Biopharma’s Recorlev (levoketoconazole) launched in 2022 as another Cushing’s drug. Any uptake of such alternatives, plus the specter of a cheaper generic mifepristone, could significantly pressure Corcept’s top line (www.sec.gov).

Another major risk is pipeline execution. The FDA’s rejection of relacorilant in Cushing’s syndrome raises doubts about Corcept’s R&D productivity and judgment. In hindsight, Corcept chose to submit relacorilant for approval even after one of its two Phase 3 trials failed to meet its primary endpoint (www.biospace.com). The FDA concluded that additional evidence was needed to establish efficacy (www.biospace.com) (www.biospace.com) – likely implying that another clinical trial (or trials) will be required (www.biospace.com). This is a costly and time-consuming setback. The company spent years and significant R&D dollars on relacorilant’s development; now that investment’s return is uncertain. Regulatory risk remains high going forward: any new trial outcome or future FDA review is unpredictable. Relacorilant’s failure also leaves Corcept’s growth plan in limbo. Management had positioned relacorilant as the next growth driver beyond Korlym (www.spglobal.com), and consensus sales forecasts had assumed approval (analysts expected relacorilant to become a potential blockbuster by 2028 before the rejection) (www.spglobal.com). With that thesis dented, Corcept’s forward earnings could stagnate or decline if nothing else fills the gap.

The current shareholder class action is another red flag. The lawsuit alleges Corcept made false or misleading statements about relacorilant’s trials and its approval likelihood (www.globenewswire.com). Essentially, investors claim the company knew (or should have known) the drug’s data were questionable – the FDA had reportedly flagged “significant review issues” during the process (www.fiercebiotech.com) – yet executives remained optimistic publicly. If discovery in the case uncovers damaging evidence (e.g. management ignoring FDA feedback or internal doubts), it could tarnish management’s credibility. At a minimum, defending the litigation will consume time and attention. That said, Corcept has navigated a securities lawsuit before (settling the Melucci case in 2024 with insurance covering the $14 million payout) (www.sec.gov). The new class action could similarly end in a settlement, but it underscores governance risk and potential weaknesses in disclosure or oversight.

Finally, Corcept faces typical biotech industry risks: reliance on key personnel (Dr. Joseph Belanoff, co-founder CEO), potential regulatory scrutiny (Korlym is essentially the abortion pill used in a different indication, carrying strict FDA prescribing rules and political sensitivities), and policy risks like drug pricing reforms. For instance, the recent IRA legislation enables Medicare to negotiate prices on certain drugs and imposes rebates for price hikes (www.sec.gov) (www.sec.gov). Korlym’s orphan drug status has protected it thus far, but over time such measures could pressure pricing. Any safety issues or adverse events with Korlym or pipeline drugs are another perennial risk that could disrupt usage or trials (www.sec.gov). In sum, Corcept’s risk profile is elevated: it has a one-product dependency under competitive/legal siege, and its pipeline has hit a roadblock. Investors should be wary of the “all eggs in one basket” situation here.

Valuation & Outlook – Open Questions

With the stock down sharply, some may see opportunity – but much depends on how open questions are resolved. Valuation remains tricky. Even at a depressed ~$25–30 share price, Corcept’s market capitalization (~$2.5–3.0 billion) still bakes in optimism that the company can overcome these hurdles. By one measure, the stock’s recent compression to ~38× earnings indicates that some risk has been priced in, but Corcept is still not obviously cheap against current fundamentals (theedgeinvestor.com) (theedgeinvestor.com). The bull case is that earnings will rebound and grow: if Corcept can successfully launch new indications (e.g. relacorilant in oncology or another cortisol modulator in a new disease), or if Korlym’s sales hold up longer than feared, the company’s profits could inflect upward. Management continues to emphasize the pipeline’s potential beyond Cushing’s. Notably, relacorilant is being studied in several oncology trials – including a Phase 3 for platinum-resistant ovarian cancer (combined with chemotherapy) – and Corcept has other candidates (e.g. miricorilant for metabolic disorders) in development (ir.corcept.com) (ir.corcept.com). If one of these efforts succeeds, it could diversify and rejuvenate the revenue stream. In fact, analysts note that the FDA’s Cushing’s rejection does not affect relacorilant’s oncology program (www.biospace.com), and Corcept has a chance to regain momentum if, for example, an approval in ovarian cancer materializes. Corcept has guided for continued revenue growth in 2026 (management gave an ambitious $900 million – $1 billion revenue target for 2026) (ir.corcept.com), implicitly assuming Korlym remains strong and perhaps anticipating a new product contribution. Hitting that target without relacorilant in Cushing’s will be challenging – it may rely on expanding Korlym’s Cushing’s market or initial oncology sales if approval comes through.

The bear case, on the other hand, is that Corcept’s earnings and share price could have further to fall. With Korlym potentially peaking, 2026 might mark the start of decline if a generic enters or doctors shift to alternatives. Investors need to consider a scenario where no new product ramps up before Korlym’s cash flows erode. In such a scenario, today’s P/E would skyrocket (as “E” drops), making the stock expensive on a forward basis. Corcept’s heavy spending on SG&A – which was tolerable while growth prospects were rosy – could become a drag if rightsizing is needed for a smaller business. Another open question is capital allocation: will Corcept continue buybacks in 2026 given its lower stock price, or conserve cash to fund a new trial for relacorilant? Notably, CEO Joseph Belanoff stated he is “confident we will find a way to get relacorilant to the patients it could help,” and the company plans to meet with FDA officials to discuss next steps (www.biospace.com). However, analysts at Truist doubt any talks can avoid additional trials, given Corcept already had chances to address FDA concerns during the first review (www.biospace.com) (www.biospace.com). If a new Phase 3 trial in Cushing’s is required, that could take several years and substantial investment – with no guarantee of success or approval even then. Is it worth it for Corcept to pursue, or should resources pivot to other projects? That strategic decision is still pending, leaving investors guessing on relacorilant’s ultimate fate.

In conclusion, Corcept’s investment narrative is at a critical juncture. The company’s finances are sturdy (cash-rich and debt-free), but its growth engine has stalled and its moat around Korlym is cracking. Shareholder lawsuits and confidence issues add to the overhang. Going forward, key markers to watch will be: Korlym’s sales trend (do they start declining as competition bites?), regulatory updates (does Corcept file for relacorilant in oncology or get any positive FDA feedback?), and legal/resolution developments (the outcome of the class action and any patent settlements). The stock’s risk/reward will hinge on whether Corcept can execute a Plan B to replace Korlym’s eventual loss and restore growth. Until clearer answers emerge on these open questions, CORT will likely remain volatile. Investors should be prepared for a wide range of outcomes – from a successful pivot that rebuilds value, to a scenario where earnings contract and the stock cheapens further. In the meantime, caution is warranted. The recent FDA rejection and court loss serve as a wake-up call, and the onus is now on Corcept’s management to chart a new path forward in order to rebuild investor trust and unlock long-term value.

Sources: Authoritative filings and company statements (SEC 10-K, press releases) and reputable financial media were used for all factual information. Key references include Corcept’s 2025 Annual Report (financials, risk factors) (www.sec.gov) (www.sec.gov), the FDA decision coverage on BioSpace (www.biospace.com) (www.biospace.com), S&P Global and FierceBiotech analyses (www.spglobal.com) (www.biospace.com), Bloomberg Law and Investing.com reports on the patent ruling (news.bloomberglaw.com) (news.bloomberglaw.com), and class action announcements via GlobeNewswire (www.globenewswire.com). These and other cited sources provide the evidentiary basis for this analysis.

For informational purposes only; not investment advice.